scholarly journals How do different eligibility guidelines for antiretroviral therapy affect the cost–effectiveness of routine viral load testing in sub-Saharan Africa?

AIDS ◽  
2014 ◽  
Vol 28 ◽  
pp. S73-S83 ◽  
Author(s):  
Ronald Scott Braithwaite ◽  
Kimberly A. Nucifora ◽  
Christopher Toohey ◽  
Jason Kessler ◽  
Lauren M. Uhler ◽  
...  
Keyword(s):  
Viral Load ◽  
Cost Effectiveness ◽  
Antiretroviral Therapy ◽  
Sub Saharan Africa ◽  
Load Testing ◽  
Viral Load Testing ◽  
Sub Saharan ◽  
The Cost

scholarly journals Point-of-Care Viral Load Testing for Sub-Saharan Africa: Informing a Target Product Profile

2016 ◽  
Vol 3 (3) ◽  
Author(s):  
Andrew N. Phillips ◽  
Valentina Cambiano ◽  
Fumiyo Nakagawa ◽  
Deborah Ford ◽  
Tsitsi Apollo ◽  
...  
Keyword(s):  
Viral Load ◽  
Point Of Care ◽  
Sub Saharan Africa ◽  
Load Testing ◽  
Viral Load Testing ◽  
Trade Offs ◽  
Art Program ◽  
Product Profile ◽  
Load Tests ◽  
Sub Saharan

Abstract Point-of-care viral load tests are being developed to monitor patients on antiretroviral therapy (ART) in sub-Saharan Africa. Test design involves trade-offs between test attributes, including accuracy, complexity, robustness, and cost. We used a model of the human immunodeficiency virus epidemic and ART program in Zimbabwe and found that the attributes of a viral load testing approach that are most influential for cost effectiveness are avoidance of a high proportion of failed tests or results not received, use of an approach that best facilitates retention on ART, and the ability to facilitate greater use of differentiated care, including through expanding coverage of testing availability.

scholarly journals Determining virological suppression and resuppression by point-of-care viral load testing in a HIV care setting in sub-Saharan Africa

2020 ◽  
Vol 18 ◽  
pp. 100231
Author(s):  
Giovanni Villa ◽  
Adam Abdullahi ◽  
Dorcas Owusu ◽  
Colette Smith ◽  
Marilyn Azumah ◽  
...  
Keyword(s):  
Viral Load ◽  
Care Setting ◽  
Point Of Care ◽  
Virological Suppression ◽  
Sub Saharan Africa ◽  
Hiv Care ◽  
Load Testing ◽  
Viral Load Testing ◽  
Sub Saharan

scholarly journals Development and validation of systems for rational use of viral load testing in adults receiving first-line ART in sub-Saharan Africa

AIDS ◽  
2011 ◽  
Vol 25 (13) ◽  
pp. 1627-1635 ◽  
Author(s):  
Michael Abouyannis ◽  
Joris Menten ◽  
Agnes Kiragga ◽  
Lutgarde Lynen ◽  
Gavin Robertson ◽  
...  
Keyword(s):  
Viral Load ◽  
Sub Saharan Africa ◽  
Load Testing ◽  
First Line ◽  
Rational Use ◽  
Viral Load Testing ◽  
Sub Saharan ◽  
Development And Validation

scholarly journals Cost-effectiveness of early versus delayed antiretroviral therapy in tuberculosis patients infected with HIV in sub-Saharan Africa

F1000Research ◽  
2017 ◽  
Vol 6 ◽  
pp. 253
Author(s):  
Rashidah T. Uthman ◽  
Olalekan A. Uthman
Keyword(s):  
Cost Effectiveness ◽  
Antiretroviral Therapy ◽  
Cost Effective ◽  
Sub Saharan Africa ◽  
Qaly Gain ◽  
Base Case ◽  
Decision Analytic Model ◽  
Life Years ◽  
Sub Saharan ◽  
The Cost

Background: The most challenging issue physicians are facing is the appropriate timing of introducing antiretroviral therapy (ART) along with ongoing tuberculosis (TB) therapy in HIV and TB co-infected patients. This study examined the cost-effectiveness of early versus delayed ART initiation in TB patients, infected with HIV (co-infected patients) in a sub-Saharan Africa setting. Methods: A decision analytic model based on previously published and real-world evidence was applied to evaluate clinical and economic outcomes associated with early versus delayed ART in TB and HIV co-infection. Incremental cost-effectiveness ratio (ICER) was calculated with both costs and quality-adjusted life years (QALYs). Different assumptions of treatment benefits and costs were taken to address uncertainties and were tested with sensitivity analyses. Results: In base case analysis, the expected cost of giving early ART to TB patients infected with HIV was $1372, with a QALY gain of 0.68, while the cost of delayed ART was $955, with a QALY gain of 0.62. The ICER shows $6775 per QALYs, which suggests that it is not as cost-effective, since it is greater than 3 x GDP per capita ($5,086) for sub-Saharan Africa willingness to pay (WTP) threshold. At $10,000 WTP, the probability that early ART is cost effective compared to delayed ART is 0.9933. At cost-effectiveness threshold of $5086, the population expected value of perfect information becomes substantial (≈US$5 million), and is likely to exceed the cost of additional investigation. This suggests that further research will be potentially cost-effective. Conclusions: From the perspective of the health-care payer in sub-Saharan Africa, early initiation of ART in HIV and TB co-infection cannot be regarded as cost-effective based on current information. The analysis shows that further research will be worthwhile and potentially cost-effective in resolving uncertainty about whether or not to start ART early in HIV and TB co-infection.

scholarly journals Realizing the potential of routine viral load testing in sub-Saharan Africa

2017 ◽  
Vol 20 ◽  
pp. e25010 ◽  
Author(s):  
Wafaa M El-Sadr ◽  
Miriam Rabkin ◽  
John Nkengasong ◽  
Deborah L Birx
Keyword(s):  
Viral Load ◽  
Sub Saharan Africa ◽  
Load Testing ◽  
Viral Load Testing ◽  
Sub Saharan
Sign in / Sign up

Export Citation Format

Share Document